QNTM
Quantum BioPharma Ltd. (QNTM) 10Y Growth Potential Analysis (2026)
Overall Score
Growth Durability
Revenue base remains effectively absent in TTM data, with revenuePerShareTTM at 0 and all margin lines at 0, indicating no demonstrated operating scale.
Inventory turnover is modest at 4.74x and the operating cycle is 77.1 days, suggesting limited efficiency despite a small working-capital base.
Profitability
TTM profitability is deeply negative, with returnOnEquityTTM at -4.13, returnOnAssetsTTM at -1.73, and returnOnInvestedCapitalTTM at -0.27.
Operating cash flow and free cash flow are both negative, with operatingCashFlowRatioTTM at -0.65 and freeCashFlowYieldTTM at -0.27, showing no current earnings power.
Financial Health
Liquidity is acceptable for now, with currentRatioTTM at 1.20, quickRatioTTM at 1.19, and cashRatioTTM at 0.44.
Leverage is low in absolute terms, with debtToAssetsRatioTTM at 0.07 and debtToEquityRatioTTM at 0.12, though interestCoverageRatioTTM is negative at -5.00 because operating earnings are still negative.
Valuation
Traditional earnings and cash-flow multiples are not supportive, with priceToFreeCashFlowRatioTTM at -3.64 and priceToOperatingCashFlowRatioTTM at -3.78 due to negative cash generation.
Book-based valuation is the only anchor, with priceToBookRatioTTM at 2.58 and priceToFairValueTTM at 2.58, but this is not enough to offset weak fundamentals.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Quantum BioPharma Ltd.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

